Search alternatives:
aromatic decrease » dramatic decrease (Expand Search)
small decrease » small increased (Expand Search)
Showing 481 - 500 results of 2,154 for search '((aromatic decrease) OR (small decrease))', query time: 0.28s Refine Results
  1. 481
  2. 482
  3. 483
  4. 484
  5. 485
  6. 486
  7. 487
  8. 488
  9. 489
  10. 490
  11. 491
  12. 492
  13. 493
  14. 494
  15. 495
  16. 496
  17. 497

    Table 3_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

    Published 2025
    “…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
  18. 498

    Table 7_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

    Published 2025
    “…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
  19. 499

    Image 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg by Joanna Palade (17712960)

    Published 2025
    “…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”
  20. 500

    Table 8_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

    Published 2025
    “…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”